Literature DB >> 9790340

Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. Lymphadenectomy Study Group.

S Pedrazzoli1, V DiCarlo, R Dionigi, F Mosca, P Pederzoli, C Pasquali, G Klöppel, K Dhaene, F Michelassi.   

Abstract

OBJECTIVE: The study was conducted to determine whether the performance of an extended lymphadenectomy and retroperitoneal soft-tissue clearance in association with a pancreatoduodenal resection improves the long-term survival of patients with a potentially curable adenocarcinoma of the head of the pancreas. SUMMARY BACKGROUND DATA: The usefulness of performing an extended lymphadenectomy and retroperitoneal soft-tissue clearance in conjunction with a pancreatoduodenal resection in the treatment of ductal adenocarcinoma of the head of the pancreas is still unknown. Published studies suggest a benefit for the procedure in terms of better long-term survival rates; however, these studies were retrospective or did not prospectively evaluate large series of patients.
MATERIALS AND METHODS: Eighty-one patients undergoing a pancreatoduodenal resection for a potentially curable ductal adenocarcinoma of the head of the pancreas were randomized to a standard (n = 40) or extended (n = 41) lymphadenectomy and retroperitoneal soft-tissue clearance in a prospective, multicentric study. The standard lymphadenectomy included removal of the anterior and posterior pancreatoduodenal, pyloric, and biliary duct, superior and inferior pancreatic head, and body lymph node stations. In addition to the above, the extended lymphadenectomy included removal of lymph nodes from the hepatic hilum and along the aorta from the diaphragmatic hiatus to the inferior mesenteric artery and laterally to both renal hila, with circumferential clearance of the origin of the celiac trunk and superior mesenteric artery. Patients did not receive any postoperative adjuvant therapy.
RESULTS: Demographic (age, gender) and histopathologic (tumor size, stage, differentiation, oncologic clearance) characteristics were similar in the two patient groups. Performance of the extended lymphadenectomy added time to the procedure, although the difference did not reach statistical significance (397 +/- 50 minutes vs. 372 +/- 50 minutes, p > 0.05). Transfusion requirements, postoperative morbidity and mortality rates, and overall survival did not differ between the two groups. When subgroups of patients were analyzed, using an a posteriori analysis that was not planned at the time of study design, there was a significantly (p < 0.05) longer survival rate in node positive patients after an extended rather than a standard lymphadenectomy. The survival curve of node positive patients after an extended lymphadenectomy could be superimposed onto the curves of node negative patients. Survival curves in node negative patients did not differ according to the magnitude of the lymphadenectomy. Multivariate analysis of all patients showed that long-term survival was affected by tumor differentiation (well vs. moderately vs. poorly differentiated, p > 0.001), diameter (< or = 2.0 cm. vs. > 2.0 cm., p < 0.01), lymph node metastasis (absent vs. present, p < 0.01) and need for 4 or more units of transfused blood (< 4 vs. > or = 4, p <0.01).
CONCLUSIONS: The addition of an extended lymphadenectomy and retroperitoneal soft-tissue clearance to a pancreatoduodenal resection does not significantly increase morbidity and mortality rates. Although the overall survival rate does not differ in the two groups, there appears to be a trend toward longer survival in node positive patients treated with an extended rather than a standard lymphadenectomy.

Entities:  

Mesh:

Year:  1998        PMID: 9790340      PMCID: PMC1191525          DOI: 10.1097/00000658-199810000-00007

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  15 in total

1.  Surgical curability and prognosis for standard versus extended resection for T1 carcinoma of the pancreas.

Authors:  K Satake; H Nishiwaki; H Yokomatsu; Y Kawazoe; K Kim; A Haku; K Umeyama; I Miyazaki
Journal:  Surg Gynecol Obstet       Date:  1992-09

2.  Surgical treatment of ductal pancreatic carcinoma.

Authors:  F P Gall; H Kessler; P Hermanek
Journal:  Eur J Surg Oncol       Date:  1991-04       Impact factor: 4.424

3.  TREATMENT OF CARCINOMA OF THE AMPULLA OF VATER.

Authors:  A O Whipple; W B Parsons; C R Mullins
Journal:  Ann Surg       Date:  1935-10       Impact factor: 12.969

4.  Survival after pancreatoduodenectomy. 118 consecutive resections without an operative mortality.

Authors:  M Trede; G Schwall; H D Saeger
Journal:  Ann Surg       Date:  1990-04       Impact factor: 12.969

5.  The surgical treatment of pancreatic carcinoma.

Authors:  M Trede
Journal:  Surgery       Date:  1985-01       Impact factor: 3.982

6.  Surgical technique, curability and postoperative quality of life in an extended pancreatectomy for adenocarcinoma of the pancreas.

Authors:  O Ishikawa
Journal:  Hepatogastroenterology       Date:  1996 Mar-Apr

7.  Regional pancreatectomy for cancer of the pancreas, ampulla, and other related sites. Tumor staging and results.

Authors:  J G Fortner
Journal:  Ann Surg       Date:  1984-04       Impact factor: 12.969

8.  Prognostic indicators for survival after resection of pancreatic adenocarcinoma.

Authors:  R J Geer; M F Brennan
Journal:  Am J Surg       Date:  1993-01       Impact factor: 2.565

9.  Survival after resection for ductal adenocarcinoma of the pancreas.

Authors:  C Sperti; C Pasquali; A Piccoli; S Pedrazzoli
Journal:  Br J Surg       Date:  1996-05       Impact factor: 6.939

10.  Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients.

Authors:  C J Yeo; J L Cameron; K D Lillemoe; J V Sitzmann; R H Hruban; S N Goodman; W C Dooley; J Coleman; H A Pitt
Journal:  Ann Surg       Date:  1995-06       Impact factor: 12.969

View more
  168 in total

Review 1.  Extent of lymphadenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas.

Authors:  S Pedrazzoli; F Michelassi
Journal:  J Gastrointest Surg       Date:  2000 May-Jun       Impact factor: 3.452

Review 2.  Adjuvant therapy in pancreatic cancer.

Authors:  P Ghaneh; J Slavin; R Sutton; M Hartley; J P Neoptolemos
Journal:  World J Gastroenterol       Date:  2001-08       Impact factor: 5.742

Review 3.  Recent advances in the surgical treatment of pancreatic cancer.

Authors:  A Shankar; R C Russell
Journal:  World J Gastroenterol       Date:  2001-10       Impact factor: 5.742

4.  Extended pancreatic resections and lymphadenectomy: An appraisal of the current evidence.

Authors:  Shailesh V Shrikhande; Savio G Barreto
Journal:  World J Gastrointest Surg       Date:  2010-02-27

5.  Pancreatic adenocarcinoma.

Authors:  Margaret A Tempero; J Pablo Arnoletti; Stephen Behrman; Edgar Ben-Josef; Al B Benson; Jordan D Berlin; John L Cameron; Ephraim S Casper; Steven J Cohen; Michelle Duff; Joshua D I Ellenhorn; William G Hawkins; John P Hoffman; Boris W Kuvshinoff; Mokenge P Malafa; Peter Muscarella; Eric K Nakakura; Aaron R Sasson; Sarah P Thayer; Douglas S Tyler; Robert S Warren; Samuel Whiting; Christopher Willett; Robert A Wolff
Journal:  J Natl Compr Canc Netw       Date:  2010-09       Impact factor: 11.908

Review 6.  The lymphatic system and pancreatic cancer.

Authors:  Darci M Fink; Maria M Steele; Michael A Hollingsworth
Journal:  Cancer Lett       Date:  2015-12-29       Impact factor: 8.679

7.  Surgery for Pancreatic and Periampullary Carcinoma.

Authors:  Abhishek Mitra; Ashwin D'Souza; Mahesh Goel; Shailesh V Shrikhande
Journal:  Indian J Surg       Date:  2015-10-10       Impact factor: 0.656

Review 8.  Indications for staging laparoscopy in pancreatic cancer.

Authors:  Antonella De Rosa; Iain C Cameron; Dhanwant Gomez
Journal:  HPB (Oxford)       Date:  2015-11-18       Impact factor: 3.647

Review 9.  Systemic Review of the Feasibility and Advantage of Minimally Invasive Pancreaticoduodenectomy.

Authors:  Chien-Hung Liao; Yu-Tung Wu; Yu-Yin Liu; Shang-Yu Wang; Shih-Ching Kang; Chun-Nan Yeh; Ta-Sen Yeh
Journal:  World J Surg       Date:  2016-05       Impact factor: 3.352

Review 10.  Survival after surgical management of pancreatic adenocarcinoma: does curative and radical surgery truly exist?

Authors:  H G Smeenk; T C K Tran; J Erdmann; C H J van Eijck; J Jeekel
Journal:  Langenbecks Arch Surg       Date:  2004-05-14       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.